Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Philippines Pilot Program Leads GSK To Lower Emerging Market Prices

This article was originally published in PharmAsia News

Executive Summary

A pilot program in the Philippines has convinced U.K.-based GlaxoSmithKline to lower the prices of some of its leading drugs in emerging markets of the world. CEO Andrew Witty said in an interview the price cuts also would increase GSK's global sales volume, one of the company's priorities. GSK is faced with efforts by other multinational drug makers to expand their business in the emerging markets, several through other business means such as acquisitions. The Philippines trial in which prices were reduced resulted in increased sales for GSK, but critics said most health care in the country is private, possibly skewing the benefits. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts